Literature DB >> 18406878

Cytogenetic analysis of a hemosiderotic fibrolipomatous tumor.

George R Wettach1, Luke J Boyd, Helen J Lawce, R Ellen Magenis, Atiya Mansoor.   

Abstract

Hemosiderotic fibrolipomatous tumor is an extremely rare, nonencapsulated, fatty lesion with a consistent histologic appearance that was originally considered reactive in nature. To our knowledge, there are no previous reports on the cytogenetics of this lesion. Reported here is a case of hemosiderotic fibrolipomatous tumor arising within the subcutaneous tissue of the right foot, dorsal aspect, of an otherwise healthy 35-year-old woman. Subsequent cytogenetic analysis revealed a clonal reciprocal translocation between chromosomes 1 and 10, with a further rearrangement involving this derivative chromosome 1 and chromosome 3. This, in addition to its characteristic morphology and immunophenotype, supports the neoplastic nature of this tumor and may aid in its diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 18406878     DOI: 10.1016/j.cancergencyto.2008.01.012

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome.

Authors:  William B Laskin; John F Fetsch; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

2.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

3.  Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.

Authors:  Cristina R Antonescu; Lei Zhang; G Petur Nielsen; Andrew E Rosenberg; Paola Dal Cin; Christopher D M Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2011-06-29       Impact factor: 5.006

4.  Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.

Authors:  Yu-Chien Kao; Valentina Ranucci; Lei Zhang; Yun-Shao Sung; Edward A Athanasian; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

5.  Radiological imaging features and clinicopathological correlation of hemosiderotic fibrolipomatous tumor: experience in a single tertiary cancer center.

Authors:  Dearbhail O'Driscoll; Edward Athanasian; Meera Hameed; Sinchun Hwang
Journal:  Skeletal Radiol       Date:  2014-12-21       Impact factor: 2.199

Review 6.  Case report: hemosiderotic fibrohistiocytic lipomatous lesion: a clinicopathologic characterization.

Authors:  Vincent M Moretti; John S J Brooks; Christian M Ogilvie
Journal:  Clin Orthop Relat Res       Date:  2010-02-02       Impact factor: 4.176

7.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

Review 8.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

9.  Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases.

Authors:  David Suster; Michael Michal; Huiya Huang; Shira Ronen; Stephanie Springborn; Maria Debiec-Rychter; Steven D Billings; John R Goldblum; Brian P Rubin; Michal Michal; Saul Suster; A Craig Mackinnon
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

10.  Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masatoshi Naito
Journal:  Genet Res Int       Date:  2011-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.